ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

“I’m grateful for treatment options like ENHERTU,” Lisa said. “I live with metastatic breast cancer. It’s in me and that’s not going to change, but I’m optimistic. In many ways, this experience has ...

New research shows that ENHERTU (trastuzumab deruxtecan) could change the standard of care treatment for metastatic HER2 positive breast cancer patients. The trial compared ENHERTU and Kadcyla, the ...